A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for The Treatment of Recurrent or Persistent Endometrial Carcinoma
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety, tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : GDC-0980
Phase: Phase 2
Ages Eligible For Study:
- Patients must have recurrent or persistent endometrial carcinoma that is refractory to curative therapy or established treatments - Histologic confirmation of the original primary tumor is required - Histologic or cytologic confirmation of the recurrent/progressive disease is desired - Patients must have had at least one but no more than two prior chemotherapeutic regimens for management of endometrial carcinoma - Disease that is measurable per RECIST v1.1 - No active infection requiring antibiotics - Any hormonal therapy directed at the malignant tumor must be discontinued at least 2 weeks prior to first study treatment - Any other prior therapy directed at the malignant tumor, including immunologic agents and radiotherapy, must be discontinued at least 2 weeks prior to first study treatment - Adequate hematologic and end organ function